These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 27080301)
1. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Pawlotsky JM Gastroenterology; 2016 Jul; 151(1):70-86. PubMed ID: 27080301 [TBL] [Abstract][Full Text] [Related]
2. The Role of RASs /RVs in the Current Management of HCV. Malandris K; Kalopitas G; Theocharidou E; Germanidis G Viruses; 2021 Oct; 13(10):. PubMed ID: 34696525 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment. Costilla V; Mathur N; Gutierrez JA Clin Liver Dis; 2015 Nov; 19(4):641-56, vi. PubMed ID: 26466653 [TBL] [Abstract][Full Text] [Related]
12. Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a. El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598 [TBL] [Abstract][Full Text] [Related]
14. Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C. Sun D; Dai M; Shen S; Li C; Yan X Gene Expr; 2018 Mar; 18(1):63-69. PubMed ID: 29221500 [TBL] [Abstract][Full Text] [Related]
16. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649 [TBL] [Abstract][Full Text] [Related]
17. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Bagaglio S; Uberti-Foppa C; Morsica G Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432 [TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279 [TBL] [Abstract][Full Text] [Related]
19. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. Bailly F; Pradat P; Virlogeux V; Zoulim F Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282 [TBL] [Abstract][Full Text] [Related]
20. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients. Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]